[Skip to Content]
[Skip to Content Landing]
Views 370
Citations 0
Comment & Response
October 2018

Regarding the Congruence Between 2 Circulating Tumor DNA Sequencing Assays

Author Affiliations
  • 1Huntsman Cancer Institute, University of Utah, Salt Lake City
  • 2Guardant Health Inc, Redwood City, California
  • 3City of Hope Comprehensive Cancer Center, Duarte, California
JAMA Oncol. 2018;4(10):1429-1430. doi:10.1001/jamaoncol.2018.2317

To the Editor The recent Research Letter1 comparing 2 cell-free DNA next-generation sequencing tests in prostate cancer has severe methodological flaws. It improperly confuses clinicians and implies that laboratory accreditation standards are lax. Published cell-free DNA test concordance study design criteria2 include: